A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

Sponsor
Eli Lilly and Company
Study ID
NCT07247084
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    Administered SC
  • Standard of Care — OTHER
    Standard of care

Study Details

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.

Key Dates

Start date
Nov 24, 2025
Status verified
Apr 2026
Primary completion
Jul 31, 2029
Completion
Jul 31, 2032

Study Design

Enrollment
3,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Tirzepatide + Standard of Care
    Participants will receive tirzepatide subcutaneously (SC) + standard of care
  • Active Comparator: Standard of Care

Primary Outcome Measure

Percent Change from Baseline in Body Weight [ Time Frame: Baseline, 24 months ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Related Studies